Super enhancers (SEs) are large clusters of transcriptional regulatory elements that promote oncogene expression, maintain malignancy, and cause cancer “transcription addiction.” They function through phase separation, 3D chromatin looping, and epigenetic modifications (e.g., H3K27ac). SE is highly cancer type specific, making it an attractive therapeutic target. Inhibitors against BRD4, CDK7/9, and strategies to disrupt phase-separated condensates show preclinical efficacy. This review summarizes the mechanisms and targeted interventions of SE.
introduction
SEs are densely clustered enhancer regions loaded with coactivators (BRD4, MED1), master transcription factors, and H3K27ac. These promote high expression of oncogenes, stemness genes, and metastasis-related genes. Cancer cells become dependent on SE-driven programs (“transcriptional addiction”), resulting in therapeutic vulnerability.
SE promotes tumor progression
SE activates oncogenes through long-range chromatin looping and chromatin remodeling (H3K27ac/crotonylation). Loss of CTCF boundaries can result in activation of immune checkpoint genes. A positive feedback loop between SE and transcription factors (e.g. PAX3-FOXO1 in rhabdomyosarcoma) locks tumor cell identity.
Epigenetics and phase separation
SE forms phase-separated transcriptional condensates through intrinsically disordered regions of BRD4 and MED1. This concentrates RNA polymerase II for efficient transcription. Histone modifications (acetylation, crotonylation) dynamically regulate SE activity. HDAC inhibitors upregulate or downregulate SE-driven oncogenes depending on dose.
Developmental reprogramming and the microenvironment
SEs hijack developmental programs (eg, fetal globin reactivation) to confer stemness. Chronic inflammation (TNFα, TRIM28) locks SE into an active state. SE also regulates immune cells. Treg-specific SEs include SNPs for autoimmune diseases. CDK7 inhibitors can suppress CAR-T-induced cytokine storm by targeting inflammatory genes caused by SE.
Carcinogenic mechanisms in specific cancers
-
HPV+cervical cancer: Viral integration creates extrachromosomal DNA (ecDNA) that fuses viral sequences and host SEs, activating global oncogenic pathways.
-
prostate cancer: BCL6/NFIB/SMAD3 SE loop promotes abiraterone resistance.
-
lymphoma: BATF3/IL-2R SE module maintains STAT/ERK signal.
-
esophageal cancer: BCLAF1 recruits p300 to the SE of POLR2A and promotes malignant transformation.
Treatment goals and strategies
-
BET inhibitor (JQ1, OTX-015): Destroys BRD4 condensate. It is effective against leukemia, TNBC, and prostate cancer.
-
CDK7/9 inhibitor (THZ1, BAY1251152): Blocks SE-driven transcription. Effective for T-ALL and small cell lung cancer.
-
epigenetic modulator: LSD1 inhibitor (NCD38) induces differentiation. HDAC/EZH2 inhibitors remodel SE activity.
-
CRISPR-dCas9 editing You can precisely silence or activate specific SEs.
-
combination therapy (BETi + immunotherapy, CDK7i + PARPi) aims to overcome resistance.
Challenges include off-target toxicity, tolerance, and tissue specificity. Recent trials have shown that BETi + PD-L1 inhibitors increase toxicity without additional benefit, highlighting the need for biomarker-based selection.
Frontiers and challenges
New technologies (HiChIP, single-cell sequencing, GRID-seq) reveal SE 3D architectures and phase-separated hubs. Limitations: SE heterogeneity, low live-cell resolution, off-target effects, and redundancy due to traditional enhancers.
conclusion
SEs drive cancer through (1) phase-separated condensates, (2) enhancer hijacking (e.g., HPV-ecDNA), and (3) metabolic epigenetic coupling (e.g., lactylation). Targeting BRD4, CDK7, or SE structures using small molecules and CRISPR is promising. Future studies should address spatiotemporal specificity and develop subtype-based combination therapies.
sauce:
Reference magazines:
Wu, D. others. (2026). A central regulatory role of super-enhancers in tumor development and targeted intervention strategies. advances in oncology. https://doi.org/10.14218/ona.2025.00029. https://www.xiahepublishing.com/2996-3427/OnA-2025-00029
